[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Precision Biosciences Inc (DTIL)

Precision Biosciences Inc (DTIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 205,083
  • Shares Outstanding, K 27,602
  • Annual Sales, $ 34,260 K
  • Annual Income, $ -45,720 K
  • EBIT $ -39 M
  • EBITDA $ -37 M
  • 60-Month Beta 1.27
  • Price/Sales 5.88
  • Price/Cash Flow N/A
  • Price/Book 4.16

Options Overview Details

View History
  • Implied Volatility 228.69% (-48.61%)
  • Historical Volatility 53.87%
  • IV Percentile 31%
  • IV Rank 16.00%
  • IV High 1,350.68% on 03/11/26
  • IV Low 14.92% on 12/16/25
  • Expected Move (DTE 3) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 25
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 1,197
  • Open Int (30-Day) 1,104
  • Expected Range 7.40 to 7.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.97
  • Number of Estimates 2
  • High Estimate $-0.74
  • Low Estimate $-1.19
  • Prior Year $-1.84
  • Growth Rate Est. (year over year) +47.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.70 +10.45%
on 07/29/26
8.05 -8.07%
on 07/20/26
-0.47 (-5.97%)
since 07/17/26
3-Month
6.00 +23.33%
on 06/03/26
9.62 -23.08%
on 07/07/26
+0.13 (+1.79%)
since 05/15/26
52-Week
3.53 +109.63%
on 02/05/26
9.62 -23.08%
on 07/07/26
+2.69 (+57.11%)
since 08/15/25

Most Recent Stories

More News
Precision BioSciences: Q2 Earnings Snapshot

Precision BioSciences: Q2 Earnings Snapshot

DTIL : 7.40 (-0.40%)
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with

TGTX : 49.28 (+1.11%)
DTIL : 7.40 (-0.40%)
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases,...

DTIL : 7.40 (-0.40%)
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

– Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy –

DTIL : 7.40 (-0.40%)
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies...

DTIL : 7.40 (-0.40%)
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies...

DTIL : 7.40 (-0.40%)
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts...

DTIL : 7.40 (-0.40%)
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026

- Webcast with Hepatitis B experts to discuss new biopsy and clinical data from the ongoing ELIMINATE-B trial in chronic hepatitis B - ...

DTIL : 7.40 (-0.40%)
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting

– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to late-juvenile...

DTIL : 7.40 (-0.40%)
Precision BioSciences: Q1 Earnings Snapshot

Precision BioSciences: Q1 Earnings Snapshot

DTIL : 7.40 (-0.40%)

Business Summary

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.

See More

Key Turning Points

3rd Resistance Point 7.67
2nd Resistance Point 7.61
1st Resistance Point 7.50
Last Price 7.40
1st Support Level 7.33
2nd Support Level 7.27
3rd Support Level 7.16

See More

52-Week High 9.62
Last Price 7.40
Fibonacci 61.8% 7.29
Fibonacci 50% 6.57
Fibonacci 38.2% 5.86
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.